Abstract
Introduction
Wound healing is a highly dynamic biological process that restores tissue integrity and relies on a balance of collagen deposition and remodelling to repair tissue at the site of an injury [1] . [3] . Exogenous TGF-␤1 exerts a predominant effect in the enhanced wound healing process through induction and deposition of ECM molecules, including collagen types I and III in excisional wounds [4] . During [5] . Numerous studies corroborate the hypothesis that TGF-␤1 plays a pivotal role in this process by enhancing ECM production and reducing inflammation [6, 7] . However, much remains to be determined regarding its mechanism of action on targets like keratinocytes and skin fibroblasts, which are the critical cell types in wound healing processes and act via production and deposition of matrix proteins, predominantly collagen types I and III [5] . Peroxisome proliferator-activated receptors (PPARs) are ligandinducible transcription factors belonging to the nuclear hormone receptor superfamily, which control many cellular and metabolic processes, including cellular differentiation and proliferation, lipid homeostasis and energy metabolism [8, 9] [10] . The promoter regions of PPAR target genes contain a direct repeat (DR1 or DR2) of the hexameric nucleotide (nt) sequence AGGTCA, separated by one or two nt [11] . [9, 12] . [13, 14] . Therefore, it has been postulated that PPAR␦ might represent a promising new therapeutic target for tissue injury [15] . A better understanding of the cellular mechanisms elicited by PPAR␦ may thus reveal its full therapeutic potential.
Of the cytokines excreted at the wound site, transforming growth factor (TGF)-␤1 represents diverse biological activities in the regulation of extracellular matrix (ECM) deposition and tissue remodelling, cellular adhesion and proliferation and the modulation of inflammatory responses [2]. TGF-␤1 signals through a complex of two membrane-associated receptors that recruit and phosphorylate Smad2 and Smad3. Phosphorylated Smad2 and Smad3 then form a heteromeric complex with Smad4 and translocate into nucleus, where they activate transcription of TGF-␤1-responsive genes in a Smad-binding element (SBE)-dependent and/or SBEindependent manner

. Three distinct PPAR subfamilies have been identified: PPAR␣ (NR1C1), PPAR␦ (NR1C2, also known as PPAR␤, FAAR and NUC1) and PPAR␥ (NR1C3). These receptors regulate gene expression by forming dimers with the retinoid X receptor (RXR) and binding to specific recognition sequences termed PPAR response elements (PPRE) located in the regulatory regions of target genes
Among the three PPAR isoforms, PPAR␦ is abundantly and ubiquitously expressed in a variety of cell lineages, including keratinocytes, and has been implicated in wound healing, inflammatory responses, embryo implantation and lipid metabolism
Recent reports demonstrated that PPAR␦ plays a pivotal role in the keratinocyte response to inflammation produced immediately after a skin injury, and its inflammation-induced activation at the wound edge maintains a number of viable keratinocytes sufficient for reepithelization
A recent report showed that TGF-␤1 is a molecular target for PPAR␦ in vascular smooth muscle cells [16] . Because TGF-␤1 is a well-known regulator of ECM homeostasis [2] [18] .
Site-directed mutagenesis
Nucleotide substitutions were introduced into the SBE and DR1 sites of the COL3A1 promoter using the QuikChange site-directed mutagenesis kit (Stratagene). PCR amplification of the wild-type human pGL3-COL3A1 luciferase reporter plasmid was performed using site-directed mutation primer sets (COL3A1-SBEmt: 5Ј -TGA AAT CTC GAG CGT AGA TT-3Ј and 5Ј -AAT CTA CGG TCG AGA TTT CA-3Ј or COL3A1-DR1mt: 5Ј -ATT TAA GAT CTA AGC AAA GGA AT-3Ј and 5Ј -ATT CCT TTG CTT AGA TCT TAA AT-3Ј
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation was performed as described previously using anti-Smad3 or anti-PPAR␦ antibodies [16] .
Rat genomic sequences containing the putative Smad3 binding site (SBE), PPAR␦ binding site (DR1) and an internal region from the COL3A1 promoter (oligo #1; -1302/-963, oligo #2; -222/-12 and oligo #3; -771/-534) were amplified using the following primer pairs: oligo #1 set 5Ј-GAAGTTGTGAGCTGGCT-CAT-3Ј and 5Ј-CAGATGAGGTCTTGGAACAG-3Ј, oligo #2 set 5Ј-TTACT-GCTGAGGGGATGGGT-3Ј and 5Ј-GCACAAAGAGTCTCATGTCT-3Ј and oligo #3 set 5Ј-ACAAGGAAGCAGTCAGGGTT-3Ј and 5Ј-TCAGGATG-GACTCTGGCAAAA-3Ј.
Statistical analyses
The significance of differences between groups was evaluated using [5, 20] (Fig. 1C) . The expression levels of these proteins were concordant with the decreased wound size in post-injury days [3] [4] [5] [6] [7] [8] (Fig. 1) . These results indicate that activation of PPAR␦ accelerates wound repair through the enhancement of expression of matrix proteins and ␣-SMA in wounded mouse tissues.
Student's t-test or repeated measurement analysis of variance (ANOVA). All data represent means Ϯ standard error (SE).
Results
Activation of PPAR␦ promotes wound healing processes
To explore the role of PPAR␦ in wound healing processes, we examined the effects of GW501516, a specific ligand of PPAR␦ [19], on wound closure and the expressional regulation of ECM-related proteins, including collagen types I and III, TGF-␤1, alpha smooth muscle actin (␣-SMA) and pSmad3, in tissues after incisional injury in the mouse. The activation of PPAR␦ by GW501516 significantly accelerated wound repair from an early time-point after injury, when compared with the vehicle-treated wounds (Fig. 1A and B). At day 8, closure of GW501516-treated wounds was almost completed, but not in the wounds exposed to vehicle (Fig. 1A). As the deposition of large amounts of matrix proteins (predominantly collagen types I and III) by peripheral cells has been implicated in the enhanced tensile strength of healing wounds, and because TGF-␤1 is the potential stimulator of ECM production
, we examined whether the ligand-activated PPAR␦ affects the expression of ECM-related proteins in wound biopsies. The administration of GW501516 markedly increased the expression of collagen types I and III, TGF-␤1, ␣-SMA and pSmad3 at days 3-8, when compared with the vehicle-treated wounds. At day 14, the enhanced expression of these molecules had gradually decayed to levels similar to those in vehicle-treated wounds
Activation of PPAR␦ enhances migration of human epidermal keratinocytes and dermal fibroblasts through TGF-␤1/Smad3 signalling pathway
The migration of keratinocytes and fibroblasts from surrounding tissues into wound sites is a well-known critical step in the process of epithelialization of the wound and ECM components, including collagen, seem to facilitate keratinocyte migration [21, 22] (Fig. S1) . The siRNA-mediated down-regulation of PPAR␦ also suppressed the GW501516-induced expression of collagen types I and III collagen and fibronectin (Fig. 4B) isoforms (2, 3, 4 and 7) , Sp-1 or c-Jun/c-Fos, which are known to mediate TGF-␤ signalling [24] . As shown in Fig. 6A , coexpression of Smad3 alone increased COL3A1 promoter activity, which was enhanced in the presence of GW501516. The effect of Smad3 was significantly attenuated by a dominant-negative form of Smad3 (Smad⌬3) in the presence or absence of GW501516 (Fig. 6B) (Fig. 6C and D) .
TGF-␤1 mediates the up-regulation of type III collagen expression by PPAR␦
As the transcriptional regulation of type III collagen is relatively poorly characterized when compared with type I collagen [23], we examined the PPAR␦-mediated regulation of type III collagen expression in more detail. To explore whether de novo protein or RNA synthesis is required for GW501516-induced expression of type III collagen, we examined the effects of actinomycin D and cycloheximide on the GW501516-induced increase in type III collagen mRNA levels. The induction of type III collagen mRNA by the PPAR␦ activator was markedly reduced in the presence of actinomycin D or cycloheximide (Fig. S2), indicating that de novo synthesis of mRNA and protein(s) that act on the type III collagen gene promoter is required for the GW501516-induced expression of type III collagen. To further characterize the role of PPAR␦ in the GW50156-induced up-regulation of type III collagen, cells were transfected with an siRNA against PPAR␦. The down-regulation of PPAR␦ expression by siRNA almost completely reversed the expression pattern of type III collagen and TGF-␤1 proteins induced by the PPAR␦ ligand. Similarly, the addition of the anti-TGF-␤1 antibody suppressed the induction of GW501516-mediated type III collagen (Fig. 5C). These results suggest that TGF-␤1 is involved in the upregulation of type III collagen by GW501516. To determine whether PPAR␦ activation induces the expression of type III collagen via TGF-␤1 at the transcriptional level, transfection assays were performed using luciferase reporter constructs driven by the COL3A1 promoter. The activation of PPAR␦ by GW501516 significantly increased COL3A1 promoter activity, which was consistent with the observed increase in type III collagen protein levels. However, while the increased promoter activity induced by GW501516 was almost completely suppressed by cotransfection with PPAR␦ siRNA, treatment with the anti-TGF-␤1 antibody partially suppressed COL3A1 promoter activity. Combined treatment with PPAR␦ siRNA and the anti-TGF-␤1 antibody completely abolished the COL3A1 promoter activity induced by GW501516 (Fig. 5D). These observations support the hypothesis that both PPAR␦ and TGF-␤1 are involved in the regulation of type III collagen expression.
Smad3 and an SBE mediated the PPAR␦-induced increase in COL3A1 promoter activity
To elucidate the mechanism involved in the TGF-␤1-mediated increase of type III collagen level by PPAR␦, we carried out a cotransfection assay using the COL3A1-luciferase reporter gene constructs and expression vectors for several different Smad
Fig. 4 Activation of PPAR␦ specifically up-regulates the mRNA levels of TGF-␤1, collagen types I and III (COL1A1, COL3A1), and fibronectin in human keratinocytes and fibroblasts. (A) Human keratinocyte-derived (HaCaT) and fibroblast-derived (Detroit551) cells were incubated for 38 hrs with indicated concentrations of GW501516. (B) Human primary epidermal keratinocytes and dermal fibroblasts were transfected with or without PPAR␦ siRNA and grown for 72 hrs, after which they were treated with GW501516 for 38 hrs in the presence or absence of anti-TGF-␤1 antibody (␣TGF-␤1
Both PPAR␦ and TGF-␤1 are involved in the transcriptional regulation of type III collagen expression
To identify the promoter region responsible for the PPAR␦-induced up-regulation of type III collagen, reporter assays were performed using a set of truncated constructs driven by the COL3A1 promoter (Fig. 7A) . The response to GW501516 was markedly reduced after deletion of sequences between nt -1494 and -1030 (relative to the transcriptional start site at ϩ1), or deletion of sequences up to nt -225 of the COL3A1 promoter (Fig. 7A) antibody. We next introduced mutations into the putative DR1 site of the COL3A1 promoter (COL3A1-DR1mt) . Surprisingly, while the response of COL3A1-DR1mt to GW501516 was similar to that of COL3A1-SBEmt, transcriptional activity was almost completely lost in the presence of the anti-TGF-␤1 antibody. These results indicate that the COL3A1 promoter is subject to dual regulation by PPAR␦ and TGF-␤1, such that PPAR␦ binds directly to a DR1-type PPRE in the COL3A1 promoter, and also induces the expression of TGF-␤1 to elicit full activation of COL3A1 expression. In support of this mechanism, simultaneous double mutation of the DR1 site and the SBE completely abolished the promoter activity of COL3A1 in response to GW501516 (Fig. 7C) .
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Fig. 5 A ligand of PPAR␦, but not of PPAR␣ or ␥, up-regulates type III collagen (COL3A1) in a TGF-␤1-dependent or -independent manner. (A) Cells were incubated for 38 hrs in low (50 nM) or high (1 M) concentrations of WY-14643 (a specific agonist of PPAR␣), GW501516 (a specific agonist of PPAR␦), troglitazone (a specific agonist of PPAR␥) or 15-deoxy-Delta 12,14-prostaglandin J2 (15-d-PGJ2; a specific agonist of PPAR␥). (B) Cells were incubated with 50 nM GW501516 for the indicated times and levels of mRNAs were analyzed by Northern blot. (C) Cells were transfected with or with
To (Fig. 7D ).
PPAR␦ and Smad3 bind to the PPRE and SBE of COL3A1 promoter
To determine whether Smad3 and PPAR␦ interact directly with the COL3A1 promoter to elicit transcriptional up-regulation, we carried out a ChIP assay. Cells were treated with GW501516 for various time periods and chromatin fragments were subjected to immunoprecipitation using anti-Smad3 or anti-PPAR␦ antibodies. Genomic DNA from the immunoprecipitates was amplified by PCR using primers that corresponded to the putative SBE or DR1 site. As shown in Fig. 8 
Discussion
A critical role for the nuclear receptor PPAR␦ in the process of tissue injury and wound repair has been suggested [7, 12] [5] . The induction of these genes was, in part, mediated by TGF-␤1, which is a master cytokine involved in the regulation of ECM homeostasis in the skin [4] . [27, 28] . In addition to the migration of cells surrounding the edge of wounds, intercellular interactions are also essential to wound healing in which ECM molecules connect the neighbouring cells [5, 21, 29] . Thus, PPAR␦-mediated induction [16] . Although the roles of all members of the PPAR family in wound healing processes have been well characterized using genetically modified mice [12] 
